Farallon Capital Management Adds $52M in Immunovant, Inc. ($IMVT)
Key Points
- Farallon Capital Management changed its Immunovant, Inc. ($IMVT) stake by 12783.3% last quarter, boosting to 1,546,000 shares worth $51.98 million.
- Wall Street's consensus rating on $IMVT is Buy and an average price target of $45.76.
- $IMVT last traded around $33.62.
Farallon Capital Management increased its position in Immunovant, Inc. ($IMVT) by 12783.3% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,546,000 shares of Immunovant, Inc. after buying 1,534,000 shares during the quarter. Farallon Capital Management's holdings in Immunovant, Inc. were worth $51.98 million as of its most recent filing.
Immunovant, Inc. ($IMVT) Stock
Immunovant, Inc. Earnings
Analysts Set New Price Targets
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.